Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Expression MEF2D by HCC cells increases their expression of PD-L1, which prevents CD8<sup>+</sup> T cell-mediated anti-tumor immunity. 31678303 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Interestingly, the combination treatment of VPA and anti-PD-L1 antibody activated IRF1/IRF8 transcriptional axis in MDSCs leading to blockade of their immunosuppressive function by downregulating the expression of IL-10, IL-6, and ARG1 while re-activating CD8<sup>+</sup> T-cells for the production of TNFα to further enhance anti-tumor immunity. 31785814 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease. 31744830 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-(L)1 that restricts anti-tumor immunity. 31732494 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Collectively, our study identifies DCLK1 as an important regulator of PD-L1 expression in pancreatic tumor and highlights a central role of DCLK1 in the regulation of tumor immunity. 31837335 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Expression of programmed death ligand 1 (PD-L1) on the surface of tumor cells and its interaction with programmed cell death protein 1 (PD-1) on tumor-infiltrating lymphocytes suppress anti-tumor immunity. 31796994 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE The addition of RANKL/RANK blockade to immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 and anti-CTLA4 antibodies is associated with increased anti-tumor immunity in mice. 31572609 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity. 30385408 2019
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.100 Biomarker phenotype BEFREE Interferon gamma has long been studied as a critical mediator of tumor immunity. 31221552 2019
Entrez Id: 1493
Gene Symbol: CTLA4
CTLA4
0.100 Biomarker phenotype BEFREE We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor burden (LTB) state in pre-clinical models as well as in melanoma patients. 30737146 2019
Entrez Id: 3604
Gene Symbol: TNFRSF9
TNFRSF9
0.100 Biomarker phenotype BEFREE Our study suggests that agonistic antibodies to CD137 can efficiently enhance anti-tumor immunity even in the setting of chronic viral infection, which might have promising therapeutic applications. 30635687 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE From these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy. 31557409 2019
Entrez Id: 1493
Gene Symbol: CTLA4
CTLA4
0.100 Biomarker phenotype BEFREE Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. 31150505 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE In contrast with this positive regulation of TAM recruitment, we found no evidence of a direct effect of ERK1/2 signaling on two other important aspects of TAM regulation by GBM cells: (1) the expression of the immune checkpoint ligands PD-L1 and PD-L2, expressed at high mRNA levels in GBM compared with other solid tumors; (2) the production of the tumor metabolite lactate recently reported to dampen tumor immunity by interacting with the receptor GPR65 present on the surface of TAM. 31467175 2019
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.100 Biomarker phenotype BEFREE A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunity. 30153900 2019
Entrez Id: 1493
Gene Symbol: CTLA4
CTLA4
0.100 Biomarker phenotype BEFREE Thus, high ADCC anti-CTLA-4 mAb is able to selectively deplete effector Treg cells and evoke tumor immunity depending on the CTLA-4-expressing status of effector CD8<sup>+</sup> T cells. 30587582 2019
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.100 Biomarker phenotype BEFREE IFNγ, a potent cytokine known to modulate tumor immunity and tumoricidal effects, is highly elevated in patients with prostate cancer after radiation. 30504123 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE This study highlights the importance of PD-L1 expression, as primarily a signature of reacting efficiency of pre-existing anti-tumor immunity, in balancing the tumor microenvironment. 31523194 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Our study identifies VGLL4 as an important regulator of PD-L1 expression and highlights a central role of VGLL4 and YAP in the regulation of tumor immunity. 30396996 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression phenotype BEFREE Experiments using bone marrow (BM) chimeric mice, generated by transferring PD-L1-KO BM cells into wild-type mice or vice versa, further suggested that PD-L1 expressed on BM-derived hematopoietic cells mediates the suppressive effects on anti-tumor immunity. 30357491 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 GeneticVariation phenotype BEFREE We also explored the associations between glycolytic activity and tumor immunity associated genetic features, including PD-L1 expression, tumor mutation burden (TMB), and tumor aneuploidy. 30935888 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. 30951669 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE These results indicate that CRISPR/Cas9-mediated PD-L1 disruption on tumor cells promotes anti-tumor immunity by increasing tumor-infiltrating lymphocytes and modulating cytokine/chemokine profiles within the tumor microenvironment, thereby suppressing ovarian cancer progression. 30702189 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Conversely, stimulating TET activity by systematic injection of its co-factor, ascorbate/vitamin C, increased chemokine and TILs, leading to enhanced anti-tumor immunity and anti-PD-L1 efficacy and extended lifespan of tumor-bearing mice. 31310587 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker phenotype BEFREE Programmed death-ligand 1 (PD-L1) is associated with the prognosis of several cancer types, and blockade of PD-1/PD-L1 signaling increases the amplitude of anti-tumor immunity. 30958600 2019